Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FID 123472 for Ocular Redness in Adults
NCT07578363Phase 3Recruiting
- Sponsor
- Alcon Inc.
- Start
- Sep 2026
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of apraclonidine in Ocular hyperemia, sponsored by Alcon Inc.. Started Sep 2026; status: recruiting.
02
Drugs
apraclonidine
03
Conditions
Ocular hyperemia
Beyond the preview
Go deeper on NCT07578363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07578363.